Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer

Study limitation reported by the research below: “Study is from a single Japanese cancer center, which may limit generalizability to other practice settings and ethnic populations.”